Baseline characteristics.

<p>LVH = Left Ventricular Hypertrophy, eGFR = estimated Glomerular Filtration Rate, UAE = Urinary Albumin Excretion</p><p>Values are given as means ± SD, medians (Q25–Q75) or proportions (%)</p><p>Baseline characteristics.</p

Association of serum erythropoietin with single-nucleotide polymorphisms (SNP).

<p>The -10log(P-value) is displayed on the y-axis, a higher value corresponds to a stronger association. Chromosome location is displayed on the x-axis. Each dot represents an individual SNP, the dark grey dots are the SNPs located in locus 6q23.</p

Relation between hemoglobin and erythropoietin in subjects with a normal or impaired renal function.

<p>Relation between hemoglobin and erythropoietin in men and women separated for normal (continuous line) and impaired renal function (dashed line) (eGFR ≥ or < 60 ml/min/1.73m²), the 95% confidence interval is depicted in grey.</p

Baseline characteristics AngII mice and controls.

<p>Baseline characteristics AngII mice and controls.</p

Circulating microRNA expression levels in AngII mice and controls.

<p>MiRNA expression levels are presented as normalized -Ct values with the median, interquartile range, minimum and maximum values. Differences between groups were not significant for all miRNAs (P>0.05).</p

Circulating microRNA expression levels in ischemic heart failure mice and controls.

<p>MiRNA expression levels are presented as normalized -Ct values with the median, interquartile range, minimum and maximum values. Differences between groups were not significant for all miRNAs (P>0.05).</p

Circulating microRNA expression levels in Ren2 rats and Sprague-Dawley controls (SD).

<p>MiRNA expression levels are presented as normalized -Ct values with the median, interquartile range, minimum and maximum values. Differences between groups were not significant for all miRNAs (P>0.05).</p

Baseline characteristics rats.

<p>Baseline characteristics rats.</p

Baseline characteristics of mice with ischemic heart failure (IHF) and controls.

<p>Baseline characteristics of mice with ischemic heart failure (IHF) and controls.</p

Additional file 1 of Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Additional file 1: Table S1. First-time initiation of therapy within new diabetes medication class* during the AFFIRM-AHF trial. Fig S1. Outcomes in the placebo arms of patients with and without diabetes. Fig S2. Outcomes with FCM vs placebo in patients with and without diabetes (COVID-19 sensitivity analysis). Fig S3. Iron parameters with FCM vs placebo in patients with and without